Trial Profile

LUMINOUS: Study to Observe the Effectiveness and Safety of Ranibizumab Through Individualized Patient Treatment and Associated Outcomes.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ranibizumab (Primary)
Indications Branch retinal vein occlusion; Central retinal vein occlusion; Diabetic macular oedema; Wet age-related macular degeneration
Focus Adverse reactions; Therapeutic Use
Acronyms LUMINOUS
Sponsors Novartis; Novartis Ophthalmics; Novartis Pharmaceuticals

Most Recent Events

01 Aug 2022 Results assessing the mean change in visual acuity, treatment exposure over year 1 and 5-year safety in treatment-naive central retinal vein occlusion patients, published in the Eye.
20 May 2016 Status changed from recruiting to completed.
03 Mar 2016 Planned number of patients changed from 26146 to 30000 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com